David Rosmarin

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 405 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

David Rosmarin, Thierry Passeron, Amit G. Pandya et al. · New England Journal of Medicine · 2022 · 266 citations

Medicine, Dermatology, Pharmacology +15

Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial

David Rosmarin, Amit G. Pandya, Mark Lebwohl et al. · The Lancet · 2020 · 253 citations

Medicine, Dermatology, Pharmacology +5

Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series

Rana Abdat, Reid A. Waldman, Valeria De Bedout et al. · Journal of the American Academy of Dermatology · 2020 · 202 citations

Veterinary Medicine, Pathobiology, Population Medicine +4

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

Atul Deodhar, Alice B. Gottlieb, Wolf‐­Henning Boehncke et al. · The Lancet · 2018 · 184 citations

Medicine, Clinical Sciences, Pharmacotherapy +7